nach oben

Erschienen in:

24.07.2020 | COVID-19 | Review Article Zur Zeit gratis

Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis

verfasst von: Yanyan Wu, Hongyu Li, Xiaozhong Guo, Eric M. Yoshida, Nahum Mendez-Sanchez, Giovanni Battista Levi Sandri, Rolf Teschke, Fernando Gomes Romeiro, Akash Shukla, Xingshun Qi

Erschienen in: Hepatology International | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Coronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients.

Methods

PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases were searched. The incidence of abnormal liver biochemical tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL), and albumin (ALB), was pooled. Risk ratio (RR) was calculated to explore the association of abnormal liver biochemical tests with severity and prognosis of COVID-19 patients.

Results

Forty-five studies were included. The pooled incidence of any abnormal liver biochemical indicator at admission and during hospitalization was 27.2% and 36%, respectively. Among the abnormal liver biochemical indicators observed at admission, abnormal ALB was the most common, followed by GGT, AST, ALT, TBIL, and ALP (39.8%, 35.8%, 21.8%, 20.4%, 8.8%, and 4.7%). Among the abnormal liver biochemical indicators observed during hospitalization, abnormal ALT was more common than AST and TBIL (38.4%, 28.1%, and 23.2%). Severe and/or critical patients had a significantly higher pooled incidence of abnormal liver biochemical indicators at admission than mild and/or moderate patients. Non-survivors had a significantly higher incidence of abnormal liver biochemical indicators than survivors (RR = 1.34, p = 0.04).

Conclusions

Abnormal liver biochemical tests are common in COVID-19 patients. Liver biochemical indicators are closely related to the severity and prognosis of COVID-19 patients.

Nur mit Berechtigung zugänglich

https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 6 May 2020

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5(4):536–544

Wu Y, Li H, Xu X, Zheng K, Qi X, Guo X. Clinical characteristics and outcomes of 2019 novel coronavirus pneumonia: a meta-analysis (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(3):240–246PubMed

Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40(5):998–1004PubMed

Chinese Digestion Association, Chinese Medical Doctor Association; Chinese Society of Hepatology, Chinese Medical Association. The protocol for prevention, diagnosis and treatment of liver injury in coronavirus disease 2019 (Article in Chinese) Zhonghua Gan Zang Bing Za Zhi 2020;28(3):217–21

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8PubMedPubMedCentral

Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020. Preprinted. https://doi.org/10.1101/2020.02.03.931766. Accessed 25 Mar 2020CrossRef

Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):97–99PubMed

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–422PubMedPubMedCentral

10.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733PubMedPubMedCentral

11.

Yang L, Wang W, Wang X, Zhao J, Xiao L, Gui W, et al. Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice. Hepatology 2019;69(1):294–313PubMed

12.

Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2(3):100113

13.

Méndez-Sánchez N, Valencia-Rodríguez A, Qi X, Yoshida EM, Romero-Gómez M, George J, et al. What has the COVID-19 pandemic taught us so far? Addressing the problem from a hepatologist's perspective. J Clin Transl Hepatol 2020;8(2):0024

14.

Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020. https://doi.org/10.1101/2020.02.26.20028191. Accessed 25 Mar 2020

15.

Li C, Li M, Gan L, Zhang Y, Lei C. Heart and liver damages in coronavirus sisease-2019 (Article in Chinese). Guangdong Med J 2020;41(9):874–877

16.

Li D, Long Y, Huang P, Guo W, Wu S, Zhou Q, et al. Clinical characteristics of 80 patients with COVID-19 in Zhuzhou City (Article in Chinese). Chin J Infect Control 2020;19(3):1–7

17.

Qi D, Yan X, Tang X, Yan X, Tang X, Peng J, et al. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. Lancet Respir Med 2020. https://ssrn.com/abstract=3546122. Accessed 6 Apr 2020

18.

Sun D, Lv G. Related factors and clinical significance of liver function damage in patients with COVID-19 (Article in Chinese). Chin J Dig Sur 2020. http://rs.yiigle.com/yufabiao/1189815.htm. Accessed 6 Apr 2020

19.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720PubMed

20.

Wang G, Wu C, Zhang Q, Zhang Q, Wu F, Yu B, et al. Epidemiological and Clinical Features of Corona Virus Disease 2019 (COVID-19) in Changsha, China. Lancet Infect Dis 2020. https://ssrn.com/abstract=3548770. Accessed 6 Apr 2020

21.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506PubMedPubMedCentral

22.

Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv 2020. https://doi.org/10.1101/2020022720029009CrossRefPubMedPubMedCentral

23.

Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69(6):1002–1009PubMed

24.

Wen K, Li W, Zhang D, Zhang A, Zhang T, Zhao P, et al. Epidemiological and clinical characteristics of 46 newly-admitted coronavirus disease 2019 cases in Beijing (Article in Chinese). Zhonghua Chuan Ran Bing Za Zhi 2020. http://rs.yiigle.com/yufabiao/1182702.htm. Accessed 6 Apr 2020

25.

Yang K, Ren M, Xiao L, Liu Y, Shi D, Lu H, et al. Epidemiological and clinical characteristics of 57 cases of new coronavirus pneumonia in non-epidemic areas (Article in Chinese). J Third Milit Med Univ 2020; 1–5

26.

Cheng K, Wei M, Shen H, Wu C, Chen D, Xiong W, et al. Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019 (Article in Chinese). Shanghai Med J 2020; 1–15

27.

Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):148–152

28.

Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2020;43(3):209–214

29.

Xu M, Li M, Zhan W, Han T, Liu L, Zhang G, et al. Clinical analysis of 23 cases of 2019 novel coronavirus infection in Xinyang City, Henan Province (Article in Chinese). Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020;32(2):421–425

30.

Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(3):229–233

31.

Zhao R, Liang Y, Lin Y, Lu L, Li Q, Li Y, et al. Clinical characteristics of 28 patients with novel coronavirus pneumonia (Article in Chinese). Zhonghua Chuan Ran Bing Za Zhi 2020. https://doi.org/10.3760/cma.j.issn.1000-6680.2020.02.000. Accessed 6 Feb 2020

32.

Wang S, Han P, Xiao F, Huang X, Cao L, Zhou Z, et al. Manifestations of liver injury in 333 hospitalized patients with coronavirus disease 2019 (Article in Chinese). Chin J Dig 2020;40(3). https://doi.org/10.3760/cma.j.issn.0254-1432.2020.03.000

33.

Zhong S, Lin F, Shi L. The clinical characteristics and outcome of 62 patients with COVID-19 (Article in Chinese). Med J Chin People's Liber Army 2020;45(4):370–374

34.

Xiang T, Liu J, Xu F, Cheng N, Liu Y, Qian K, et al. Analysis of clinical characteristics of 49 patients with Novel Coronavirus Pneumonia in Jiangxi province (Article in Chinese). Chin J Respir Crit Care Med 2020;19(2):1–7

35.

Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 2020;92(7):797–806PubMed

36.

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606PubMedPubMedCentral

37.

Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020;80(4):388–393PubMedPubMedCentral

38.

Yao N, Wang SN, Lian JQ, Sun YT, Zhang GF, Kang WZ, et al. Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28:E003. https://doi.org/10.3760/cma.j.cn501113-20200226-00070CrossRef

39.

Ma Y, Xia S, Wang M, Zhang S, Du W, Chen Q, et al. Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases (Article in Chinese). Zhongguo Dang Dai Er Ke Za Zhi 2020;22(4):1–4

40.

Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323(15):1488–1494

41.

Zhou Y, Zhu C, Wan X, Feng C. Clinical characteristics and laboratory results of 3886 patients with fever and cough (Article in Chinese). Lab Med Clin 2020;17(11):1541–1545

42.

Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020;ciaa247. https://doi.org/10.1093/cid/ciaa247

43.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55(5):2000524PubMedPubMedCentral

44.

Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80(6):639–645PubMedPubMedCentral

45.

Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int 2020;40(6):1321–1326PubMed

46.

Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115(5):766–773PubMed

47.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020. https://doi.org/10.1016/j.jhep.2020.04.006CrossRefPubMedPubMedCentral

48.

Sun C, Zhang XB, Dai Y, Xu XZ, Zhao J. Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province (Article in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2020;43:E042. https://doi.org/10.3760/cma.j.cn112147-20200224-00168

49.

Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 2020;24(6):3404–3410PubMed

50.

Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21(1):74PubMedPubMedCentral

51.

Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020. https://doi.org/10.1111/liv.14455CrossRefPubMedPubMedCentral

52.

Fang XW, Mei Q, Yang TJ, Zhang L, Yang Y, Wang YZ, et al. Clinical characteristics and treatment strategies of 79 patients with COVID-19 (Article in Chinese). Chin Pharmacol Bull 2020;36(04):453–459

53.

Li GM, Pan X. Features of liver injury in patients with coronavirus disease 2019 in Bozhou, China (Article in Chinese). J Clin Hepatol 2020;36(4):772–774

54.

Wang XF, Zhou ZQ, Yang HH, Tian F, Wang CF, Cui GZ, et al. Extrapulmonary organ damage and clinical significance in patients with coronavirus disease 2019 (Article in Chinese). Zhejiang Med 2020;42(5):485–488 (+96)

55.

Yuan J, Sun YY, Zuo YJ, Chen TY, Cao Q, Yuan GD, et al. A retrospective analysis of the clinical characteristica of 223 NCP patients in Chongqing (Article in Chinese). J Southwest Univ (Natural Science Edition) 2020;42(3):17–24

56.

Bai P, He W, Zhang X, Liu S, Jin J. Analysis of clinical features of 58 patients with severe or critical 2019 novel coronavirus pneumonia (Article in Chinese). Zhonghua Ji Zhen Yi Xue Za Zhi 2020;4:483–487

57.

Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. Lancet Respira Med 2020. https://ssrn.com/abstract=3548785. Accessed 25 Mar 2020

58.

Li L, Li S, Xu M, Yu P, Zheng S, Duan Z, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. medRxiv 2020. https://doi.org/10.1101/2020.02.28.20028514

59.

Jeong H, Min S, Chae H, Kim S, Lee G, Namgoong SK, et al. Chloroquine and lopinavir (COVID-19 Drug Candidates) signal amplification by reversible exchange. ChemRxiv 2020. https://www.researchgate.net/publication/340387695_Chloroquine_and_Lopinavir_COVID-19_Drug_Candidates_Signal_Amplification_by_Reversible_Exchange. Accessed 6 Apr 2020

60.

Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV -associated tuberculosis in Vietnam. PLoS One 2014;9(1):e84866PubMedPubMedCentral

61.

Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007;11(3):525–548 (vi)PubMed

62.

Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi 2020;28(2):100–106

63.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020;38(1):1–9PubMed

64.

Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang XZ, Wang WJ, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med 2018;24(1):73–83PubMed

65.

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148(7):1340–1352e7PubMed

66.

Giner GV, Oltra M, Rueda D. Esteban MJ, Redón J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connnective tissue disease. Clin Rheumatol 2007;26:971–972

67.

Chen D, Yang F, Luo Z, Xie H, Dong H, Jia L. Current status and bottle-necks of global pharmaceutical developments against COVID-19 (Article in Chinese). Chin Pharmacol Bull 2020;36(4):1–11

68.

Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, et al. Methylprednisolone-related liver injury: a descriptive study using the French pharmacovigi-lance database. Clin Res Hepatol Gastroenterol 2020; p. S2210-7401(19)30270-0

69.

Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis. Liver Int 2020;40(6):1316–1320PubMed

70.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84PubMed

71.

Li Y, De Stefano V, Li H, Zheng K, Bai Z, Guo X, et al. Epidemiology of Budd-Chiari syndrome: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019;43(4):468–474PubMed

Titel: Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis
verfasst von: Yanyan Wu
Hongyu Li
Xiaozhong Guo
Eric M. Yoshida
Nahum Mendez-Sanchez
Giovanni Battista Levi Sandri
Rolf Teschke
Fernando Gomes Romeiro
Akash Shukla
Xingshun Qi
Publikationsdatum: 24.07.2020
Verlag: Springer India
Schlagwort: COVID-19
Erschienen in: Hepatology International / Ausgabe 5/2020
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10074-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background and aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation

HCC with portal vein tumor thrombosis: how to manage?

Interleukin-22 in alcoholic hepatitis and beyond

Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis

Liver injury in remdesivir-treated COVID-19 patients